Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;29(11):2943-71.
doi: 10.1007/s11095-012-0828-z. Epub 2012 Jul 20.

An overview of tubulin inhibitors that interact with the colchicine binding site

Yan Lu  1 , Jianjun Chen, Min Xiao, Wei Li, Duane D Miller
Affiliations
Review

An overview of tubulin inhibitors that interact with the colchicine binding site

Yan Lu et al. Pharm Res. 2012 Nov.

Abstract

Tubulin dynamics is a promising target for new chemotherapeutic agents. The colchicine binding site is one of the most important pockets for potential tubulin polymerization destabilizers. Colchicine binding site inhibitors (CBSI) exert their biological effects by inhibiting tubulin assembly and suppressing microtubule formation. A large number of molecules interacting with the colchicine binding site have been designed and synthesized with significant structural diversity. CBSIs have been modified as to chemical structure as well as pharmacokinetic properties, and tested in order to find a highly potent, low toxicity agent for treatment of cancers. CBSIs are believed to act by a common mechanism via binding to the colchicine site on tubulin. The present review is a synopsis of compounds that have been reported in the past decade that have provided an increase in our understanding of the actions of CBSIs.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Tubulin binding sites (BS) of microtubule targeting agents.
Fig. 2
Fig. 2
Publications related to CBSIs over last decades from PubMed (data entry implementation date until Dec 30th, 2011).
Fig. 3
Fig. 3
Chemical structures of established drugs bound to colchicine binding site and CBSIs in clinical trials (TMP: 3, 4, 5-trimethoxyphenyl).
Fig. 4
Fig. 4
Interactions between the pharmacophoric points and the tubulin structure (based on Ref. (60)).
Fig. 5
Fig. 5
Chemical structures of chemical modified CA-4 analogs.
Fig. 6
Fig. 6
Chemical structures of chemical modified CA-4 analogs (continued).
Fig. 7
Fig. 7
Chemical structures of indole, quinolone and thiophene-based CBSIs.
Fig. 8
Fig. 8
Chemical structures of chalcone analogs.
Fig. 9
Fig. 9
Chemical structures of sulfonamide CBSIs.
Fig. 10
Fig. 10
Chemical structures of 2-ME analogs.
Fig. 11
Fig. 11
Chemical structures of CBSIs derivatives of natural products.
Fig. 12
Fig. 12
Chemical structures of CBSIs covalently binding to tubulin colchicine binding site.
Fig. 13
Fig. 13
Chemical structures of screened and synthesized CBSIs.
Fig. 14
Fig. 14
Chemical structures of prodrugs of CBSIs.
Fig. 15
Fig. 15
Chemical structures of CBSIs with improved solubility.
See this image and copyright information in PMC

References

    1. Pryor DE, O’Brate A, Bilcer G, Diaz JF, Wang Y, Kabaki M, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41:9109–15. - PubMed
    1. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, et al. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435:519–22. - PubMed
    1. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428:198–202. - PubMed
    1. Seveand P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? The Lancet Oncology. 2008;9:168–75. - PubMed
    1. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010;102:316–24. - PMC - PubMed

Publication types